Gene · 51206
Papers3,850
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,850
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Effects of SGLT2-Inhibitors on Comprehensive Geriatric Assessment, Biomarkers of Oxidative Stress, and Platelet Activation in Elderly Diabetic Patients with Heart Failure with Preserved Ejection Fraction. | Int J Mol Sci | 2024 | 39201499 | PubTator, text mining | PubMed |
| The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice. | Eur Heart J | 2024 | 39150906 | PubTator, text mining | PubMed |
| Dalby A, Mezzano D, Rivera J, et al. Introduction of an ancient founder glycoprotein VI mutation into the Chilean population. Blood Adv. 2022;6(22):5866-5869. | Blood Adv | 2024 | 39150735 | PubTator, text mining | PubMed |
| Screening for biomarkers of tuberous sclerosis complex-associated epilepsy: a bioinformatics analysis. | Transl Pediatr | 2024 | 39144436 | PubTator, text mining | PubMed |
| Mendelian Randomization and Bayesian Colocalization Analysis Implicate Glycoprotein VI as a Potential Drug Target for Cardioembolic Stroke in South Asian Populations. | J Am Heart Assoc | 2024 | 39119976 | PubTator, text mining | PubMed |
| Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice. | Blood Adv | 2024 | 38968150 | PubTator, text mining | PubMed |
| Recurrent Cerebral Hemorrhaging with Platelet Dysfunction Accompanied by Anti-glycoprotein VI Autoantibodies in a Patient with TAFRO Syndrome. | Intern Med | 2024 | 38945933 | PubTator, text mining | PubMed |
| Bidirectional Two-Sample Mendelian Randomization Study of Immunoglobulin G N-Glycosylation and Senescence-Associated Secretory Phenotype. | Int J Mol Sci | 2024 | 38928043 | PubTator, text mining | PubMed |
| Platelet Activation Pathways Controlling Reversible Integrin αIIbβ3 Activation. | TH Open | 2024 | 38911141 | PubTator, text mining | PubMed |
| Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets. | Platelets | 2024 | 38904212 | PubTator, text mining | PubMed |
Corrigendum to 'Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2 and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand': Journal of Thrombosis and Haemostasis, Volume 22, Issue 1, (January 2024) Pages 271-285. | J Thromb Haemost | 2024 | 38902124 | PubTator, text mining | PubMed |
| Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic target. | Blood | 2024 | 38900973 | PubTator, text mining | PubMed |
| Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial. | PLoS One | 2024 | 38885234 | PubTator, text mining | PubMed |
| Platelet mass cytometry reveals dysregulation of prothrombotic pathways in essential thrombocythemia. | Platelets | 2024 | 38845541 | PubTator, text mining | PubMed |
| Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer. | Blood Adv | 2024 | 38838227 | PubTator, text mining | PubMed |
| A deep eutectic solvent is an effective cryoprotective agent for platelets. | Cryobiology | 2024 | 38815783 | PubTator, text mining | PubMed |
| The LAT Rheostat as a Regulator of Megakaryocyte Activation. | Thromb Haemost | 2024 | 38788774 | PubTator, text mining | PubMed |
| Cardiovascular and genetic determinants of platelet high responsiveness: results from the Gutenberg Health Study. | Blood Adv | 2024 | 38776438 | PubTator, text mining | PubMed |
| Linking Computational Fluid Dynamics Modeling to Device-Induced Platelet Defects in Mechanically Assisted Circulation. | ASAIO J | 2024 | 38768482 | PubTator, text mining | PubMed |
| Single molecule studies of dynamic platelet interactions with endothelial cells. | Front Bioeng Biotechnol | 2024 | 38638321 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51206/papers?page=9